Roivant Sciences $230 million stock offering
We advised the company on its SEC-registered offering
Davis Polk advised Roivant Sciences Ltd. in connection with its $230 million SEC-registered offering of 30,666,665 common shares (which includes the exercise in full by the underwriters of their option to purchase up to 3,999,999 additional shares).
Roivant’s mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch “Vants” – nimble and focused biopharmaceutical and health technology companies.
The Davis Polk corporate team included partner Derek Dostal, counsel Stephen A. Byeff and associate Soo Kyung Chae. Counsel Sarah E. Kim and Matthew R. Silver provided 1940 Act advice. Partners Patrick E. Sigmon, Jonathan Cooklin and Kara L. Mungovan provided tax advice. The intellectual property and technology transactions team included partner David R. Bauer and associate Alison T. Chin. Members of the Davis Polk team are based in the New York and London offices.